BACKGROUND: This paper details the results of an evaluation of the level of consensus amongst clinicians on the use of ataluren in both ambulatory and non-ambulatory patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). The consensus was derived using a modified Delphi methodology that involved an exploration phase and then an evaluation phase. METHODS: The exploration phase involved 90-minute virtual 1:1 interviews of 12 paediatric neurologists who cared for 30-120 DMD patients each and had patient contact every one or two weeks. The respondents managed one to ten nmDMD patients taking ataluren. The Discussion Guide for the interviews can be viewed as Appendix A. Following the exploration phase interviews, the interview transcripts were analysed by an independent party to identify common themes, views and opinions and developed 43 draft statements that the Steering Group (authors) reviewed, refined and endorsed a final list of 42 statements. Details of the recruitment of participants for the exploration and evaluation phases can be found under the Methods section. RESULTS: A consensus was agreed (> 66% of respondents agreeing) for 41 of the 42 statements using results from a consensus survey of healthcare professionals (n = 20) experienced in the treatment of nmDMD. CONCLUSIONS: The statements with a high consensus suggest that treatment with ataluren should be initiated as soon as possible to delay disease progression and allow patients to remain ambulatory for as long as possible. Ataluren is indicated for the treatment of Duchenne muscular dystrophy that results from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older (see Summary of Product Characteristics for each country).

Department of Child Adolescent and Developmental Neurology Ljubljana University Medical Centre Ljubljana Slovenia

Department of Pediatric Neurology Faculty of Medicine University Hospital Brno Masaryk University in Brno Brno Moravia Czech Republic

Department of Women's and Children's Health Karolinska Institute Stockholm Sweden

MASS Team Suite 99 95 Mortimer Street London W1W 7GB UK

Zobrazit více v PubMed

Blake DJ, Weir A, Newey SE, Davies Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82:291–329. doi: 10.1152/physrev.00028.2001. PubMed DOI

Hoffman EP, Bronson A, Levin AA, et al. Restoring Dystrophin expression in Duchenne muscular dystrophy muscle. Am J Pathol. 2011;179(1):12–22. doi: 10.1016/j.ajpath.2011.03.050. PubMed DOI PMC

Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 2004;5(8):872–6. doi: 10.1038/sj.embor.7400221. PubMed DOI PMC

Ciafaloni E, Moxley RT. Treatment options for Duchenne muscular dystrophy. Curr Treat Options Neurol. 2008;10(2):86–93. doi: 10.1007/s11940-008-0010-4. PubMed DOI

Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251–67. doi: 10.1016/S1474-4422(18)30025-5. PubMed DOI PMC

Dubow JS, Meyer JM, Deflazazacoer Review US Neurol. 2016;12(1):12–6. doi: 10.17925/USN.2016.12.01.12. DOI

Matthews E, et al. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;5:CD003725. doi: 10.1002/14651858.CD003725.pub4. PubMed DOI PMC

Gloss D, et al. Practical guideline update summary. Corticosteroid treatment of Duchenne muscular dystrophy report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465–72. doi: 10.1212/WNL.0000000000002337. PubMed DOI PMC

Translarna® Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/medicine/33294. Last accessed July 2022.

Michael E, Sofou K, Wahlgren L, et al. Long term treatment with ataluren – the Swedish experience. BMC Musculoskelet Disord. 2021;22(1):837–47. doi: 10.1186/s12891-021-04700-z. PubMed DOI PMC

McDonald CM, Muntoni F, Penematsa et al. Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients. J Comp Eff Res. 2021;11(3):139–155. doi: 1 0.2217/cer-2021-0196. PubMed PMC

Birnkrant J, Bello L, Butterfield RJ, et al. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet. 2022;10(4):403–20. doi: 10.1016/s2213-2600(21)00581-6. PubMed DOI

Health Knowledge. The use of Delphi methods. Available from https://www.healthknowledge.org.uk/public-health-textbook/research-methods/1c-health-care-evaluation-health-care-assessment/use-delphi-methods Last accessed January 2024.

Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol. 2021;11(4):116–29. doi: 10.5662/wjm.v11.i4.116. PubMed DOI PMC

Aguado JM, et al. J Hosp Infect. 2015;90:117–25. doi: 10.1016/j.jhin.2015.03.001. PubMed DOI

Robertson DA, et al. Diabetes Ther. 2019;10(3):901–16. doi: 10.1007/s13300-019-0598-2. PubMed DOI PMC

Orme S, et al. Nurs Residential Care. 2022;24(3):24–37. doi: 10.12968/nrec.2021.0013. DOI

Burton JO, et al. Eur J Heart Fail. 2022;24:1467–77. doi: 10.1002/ejhf.2612. PubMed DOI PMC

Schmidt S, Hafner P, Klein A, et al. Timed function tests, motor function measure, and quantitative thigh muscle MRI in ambulant children with Duchenne muscular dystrophy: a cross-sectional analysis. Neuro Dis. 2018;28(1):16–23. doi: 10.1016/j.nmd.2017.10.003. PubMed DOI

Janssen MMHP, et al. Variables associated with upper extremity function in patients with Duchenne muscular dystrophy. J Neurol. 2016;263(9):1810–8. doi: 10.1007/s00415-016-8193-1. PubMed DOI PMC

Szabo SM, et al. The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systemic literature review. Orphanet J Rare Dis. 2021;161(1):237–50. doi: 10.1186/s13023-021-01862-w. PubMed DOI PMC

Choi Y-A, Shin H-L, Shin H-L. Scoliosis in Duchenne muscular dystrophy children is fully reducible in the initial stage and becomes structural over time. BMC Muscuoloskeletal Disorders. 2019;20:86–93. doi: 10.1186/s12891-019-2661-6. PubMed DOI PMC

Bartels B, et al. Upper limb function in adults with Duchenne muscular dystrophy. J Rehabil Med. 2011;43(9):770–5. doi: 10.2340/16501977-0841. PubMed DOI

Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477–87. doi: 10.1002/mus.24332. PubMed DOI PMC

Campbell C, Barohn RJ, Bertini E, et al. Meta-analyses of ataluren randomized controlled trials in nonsense mutation duchenne muscular dystrophy. J Comp Eff Res. 2020;9(14):973–84. doi: 10.2217/cer-2020-0095. PubMed DOI

Finkel RS, Flanigan KM, Wong B, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation duchenne muscular dystrophy. PLoS ONE. 2013;8(12):e81302. doi: 10.1371/journal.pone.0081302. PubMed DOI PMC

McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation duchennemusculardystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489–98. doi: 10.1016/S0140-6736(17)31611-2. PubMed DOI

Mercuri E, Muntoni F, Osorio AN, et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res. 2020;9(5):341–60. doi: 10.2217/cer-2019-0171. PubMed DOI PMC

Muntoni F, Desguerre I, Guglieri M, et al. Ataluren use in patients with nonsense mutation duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry. J Comp Eff Res. 2019;8(14):1187–200. doi: 10.2217/cer-2019-0086. PubMed DOI